Aliquoting dramatically reduces these exposures
Your clinical staff stops spending 12-13 hours per week on PA paperwork
The Category 2 Ban and the 2026 Reclassification In 2023, the FDA pulled 19 of the most popular peptides BPC-157, TB-500, CJC-1295, among others off the compounding-permitted list and placed them on the restricted Category 2 list, citing safety concerns, impurity issues, and a lack of clinical data
This is why supplementation is often recommended
Conversely, patients with genetically determined IL1B, IL6 and IFNG-driven inflammatory response seem to benefit the least from anti-TNF therapy
This is the highest local concentration possible and produces the strongest local regenerative signal